187 related articles for article (PubMed ID: 23155442)
1. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
Forthun RB; Sengupta T; Skjeldam HK; Lindvall JM; McCormack E; Gjertsen BT; Nilsen H
PLoS One; 2012; 7(11):e48992. PubMed ID: 23155442
[TBL] [Abstract][Full Text] [Related]
2. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Rücker FG; Lang KM; Fütterer M; Komarica V; Schmid M; Döhner H; Schlenk RF; Döhner K; Knudsen S; Bullinger L
Epigenetics; 2016 Jul; 11(7):517-25. PubMed ID: 27309669
[TBL] [Abstract][Full Text] [Related]
3. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
4. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
6. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
10. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
11. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells.
Biermann J; Boyle J; Pielen A; Lagrèze WA
Mol Vis; 2011 Feb; 17():395-403. PubMed ID: 21311741
[TBL] [Abstract][Full Text] [Related]
13. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Whitman SP; Hackanson B; Liyanarachchi S; Liu S; Rush LJ; Maharry K; Margeson D; Davuluri R; Wen J; Witte T; Yu L; Liu C; Bloomfield CD; Marcucci G; Plass C; Caligiuri MA
Blood; 2008 Sep; 112(5):2013-6. PubMed ID: 18566324
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
15. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
[TBL] [Abstract][Full Text] [Related]
16. Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats.
Citraro R; Leo A; De Caro C; Nesci V; Gallo Cantafio ME; Amodio N; Mattace Raso G; Lama A; Russo R; Calignano A; Tallarico M; Russo E; De Sarro G
Mol Neurobiol; 2020 Jan; 57(1):408-421. PubMed ID: 31368023
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
Salmon JM; Todorovski I; Stanley KL; Bruedigam C; Kearney CJ; Martelotto LG; Rossello F; Semple T; Arnau GM; Zethoven M; Bots M; Bjelosevic S; Cluse LA; Fraser PJ; Litalien V; Vidacs E; McArthur K; Matthews AY; Gressier E; de Weerd NA; Lichte J; Kelly MJ; Hogg SJ; Hertzog PJ; Kats LM; Vervoort SJ; De Carvalho DD; Scheu S; Bedoui S; Kile BT; Lane SW; Perkins AC; Wei AH; Dominguez PM; Johnstone RW
Cancer Discov; 2022 Jun; 12(6):1560-1579. PubMed ID: 35311997
[TBL] [Abstract][Full Text] [Related]
18. Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats.
Cho HM; Seok YM; Lee HA; Song M; Kim I
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424007
[TBL] [Abstract][Full Text] [Related]
19. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.
Milutinovic S; D'Alessio AC; Detich N; Szyf M
Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225
[TBL] [Abstract][Full Text] [Related]
20. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]